PMID

Data

Article Title

Organization

A Rational Design of a Selective Inhibitor for Kv1.1 Channels Prevalent in Demyelinated Nerves That Improves Their Impaired Axonal Conduction.

Dublin Institute of Technology

Pharmaceutical Optimization of Peptide Toxins for Ion Channel Targets: Potent, Selective, and Long-Lived Antagonists of Kv1.3.

Amgen

Cortisone dissociates the Shaker family K+ channels from their beta subunits.

Columbia University College of Physicians and Surgeons

Disruption of Kv1.1 N-type inactivation by novel small molecule inhibitors (disinactivators).

Wyeth Research

Selective Kv1.5 blockers: development of (R)-1-(methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxyphenyl)-2-imidazolidinone (KVI-020/WYE-160020) as a potential treatment for atrial arrhythmia.

Wyeth Research

A new class of blockers of the voltage-gated potassium channel Kv1.3 via modification of the 4- or 7-position of khellinone.

Institute of Medical Research Biotechnology Centre

Alkoxypsoralens, novel nonpeptide blockers of Shaker-type K+ channels: synthesis and photoreactivity.

University of Kiel

The discovery and optimization of benzimidazoles as selective Na

Pfizer

Clathrodin, hymenidin and oroidin, and their synthetic analogues as inhibitors of the voltage-gated potassium channels.

University of Ljubljana

Methods of use of cyclopamine analogs

Infinity Pharmaceuticals

Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.

Kochi Medical School